JP2024506751A5 - - Google Patents
Info
- Publication number
- JP2024506751A5 JP2024506751A5 JP2023570335A JP2023570335A JP2024506751A5 JP 2024506751 A5 JP2024506751 A5 JP 2024506751A5 JP 2023570335 A JP2023570335 A JP 2023570335A JP 2023570335 A JP2023570335 A JP 2023570335A JP 2024506751 A5 JP2024506751 A5 JP 2024506751A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- sequence
- combination according
- cells
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21154639 | 2021-02-01 | ||
| EP21154639.5 | 2021-02-01 | ||
| PCT/EP2022/052372 WO2022162247A1 (en) | 2021-02-01 | 2022-02-01 | Gene silencing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024506751A JP2024506751A (ja) | 2024-02-14 |
| JP2024506751A5 true JP2024506751A5 (enExample) | 2025-02-10 |
Family
ID=74494852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023570335A Pending JP2024506751A (ja) | 2021-02-01 | 2022-02-01 | 遺伝子サイレンシング |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240139319A1 (enExample) |
| EP (1) | EP4284932A1 (enExample) |
| JP (1) | JP2024506751A (enExample) |
| KR (1) | KR20230152689A (enExample) |
| CN (1) | CN117413062A (enExample) |
| AU (1) | AU2022213505A1 (enExample) |
| CA (1) | CA3207166A1 (enExample) |
| GB (1) | GB2617799B (enExample) |
| IL (1) | IL304840A (enExample) |
| MX (1) | MX2023009036A (enExample) |
| WO (1) | WO2022162247A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2625500B (en) | 2021-09-21 | 2026-04-01 | Scribe Therapeutics Inc | Engineered CasX repressor systems |
| GB2634837A (en) | 2022-06-07 | 2025-04-23 | Scribe Therapeutics Inc | Compositions and methods for the targeting of PCSK9 |
| US20250387518A1 (en) * | 2022-06-23 | 2025-12-25 | Nchroma Bio, Inc. | Compositions and methods for epigenetic regulation of b2m expression |
| KR20250077608A (ko) | 2022-08-19 | 2025-05-30 | 튠 쎄라퓨틱스, 인코포레이티드 | 표적 유전자 억제를 통한 b형 간염 바이러스 조절용 조성물, 시스템 및 방법 |
| PE20251319A1 (es) * | 2022-09-13 | 2025-05-16 | Arsenal Biosciences Inc | Celulas inmunitarias que coexpresan arnhc de tgfbr |
| IL319704A (en) * | 2022-09-23 | 2025-05-01 | Nchroma Bio Inc | Compositions and methods for epigenetic regulation of HBV gene expression |
| WO2024081879A1 (en) * | 2022-10-14 | 2024-04-18 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of cd247 expression |
| IL322949A (en) | 2023-03-03 | 2025-10-01 | Arsenal Biosciences Inc | Systems targeting PSMA and CA9 |
| PE20252746A1 (es) * | 2023-03-29 | 2025-12-05 | Scribe Therapeutics Inc | Composiciones y metodos para el direccionamiento a pcsk9 |
| AU2024270764A1 (en) | 2023-05-15 | 2025-12-04 | Nchroma Bio, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| WO2024238700A1 (en) * | 2023-05-15 | 2024-11-21 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| WO2025049792A1 (en) * | 2023-09-01 | 2025-03-06 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of tgfbr2 expression |
| CN120683098A (zh) * | 2025-06-26 | 2025-09-23 | 湖北煜辰达生物科技有限公司 | 嵌合体逆转录引物及其在精准基因编辑中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5723315A (en) | 1996-08-23 | 1998-03-03 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| WO1998005635A1 (en) | 1996-08-07 | 1998-02-12 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| WO2015161276A2 (en) * | 2014-04-18 | 2015-10-22 | Editas Medicine, Inc. | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
| GB201418965D0 (enExample) * | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| WO2016094872A1 (en) * | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Dead guides for crispr transcription factors |
| KR20230156800A (ko) * | 2015-03-03 | 2023-11-14 | 더 제너럴 하스피탈 코포레이션 | 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제 |
| US20180251789A1 (en) * | 2015-09-04 | 2018-09-06 | Massachusetts Institute Of Technology | Multilayer genetic safety kill circuits based on single cas9 protein and multiple engineered grna in mammalian cells |
| MX2019013514A (es) * | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| MX2019014640A (es) * | 2017-06-09 | 2020-10-05 | Editas Medicine Inc | Nucleasas de repeticiones palíndromicas agrupadas y regularmente interespaciadas de proteina asociada 9 (cas9) genomanipuladas. |
| US20200123567A1 (en) * | 2017-06-26 | 2020-04-23 | Samira Kiani | A universal platform to enhance crispr-based gene editing for in vivo therapies |
| KR102922694B1 (ko) * | 2018-04-19 | 2026-02-03 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 유전자 편집을 위한 조성물 및 방법 |
-
2022
- 2022-02-01 CA CA3207166A patent/CA3207166A1/en active Pending
- 2022-02-01 JP JP2023570335A patent/JP2024506751A/ja active Pending
- 2022-02-01 EP EP22704338.7A patent/EP4284932A1/en active Pending
- 2022-02-01 AU AU2022213505A patent/AU2022213505A1/en active Pending
- 2022-02-01 CN CN202280025035.3A patent/CN117413062A/zh active Pending
- 2022-02-01 WO PCT/EP2022/052372 patent/WO2022162247A1/en not_active Ceased
- 2022-02-01 US US18/274,752 patent/US20240139319A1/en active Pending
- 2022-02-01 KR KR1020237029816A patent/KR20230152689A/ko active Pending
- 2022-02-01 MX MX2023009036A patent/MX2023009036A/es unknown
- 2022-02-01 GB GB2312522.2A patent/GB2617799B/en active Active
-
2023
- 2023-07-30 IL IL304840A patent/IL304840A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024506751A5 (enExample) | ||
| GB2617799A (en) | Gene silencing | |
| US12227549B2 (en) | RNA encoding a therapeutic protein | |
| Klemenz et al. | αB crystallin accumulation is a specific response to Ha-ras and v-mos oncogene expression in mouse NIH 3T3 fibroblasts | |
| US12447213B2 (en) | Modulation of novel immune checkpoint targets | |
| JP7490704B2 (ja) | 遺伝子組換えにより内在性ｆｏｘｐ３遺伝子の発現が安定化されたｃｄ４ ｔ細胞を使用した自己免疫疾患の治療方法 | |
| Prelich et al. | Functional identity of proliferating cell nuclear antigen and a DNA polymerase-δ auxiliary protein | |
| CN104981478B (zh) | 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物 | |
| AU2024202988A1 (en) | Interleukin-2-Fc fusion proteins and methods of use | |
| JP2022547168A5 (enExample) | ||
| CN104768967B (zh) | 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物 | |
| US20190106678A1 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 | |
| US7960357B2 (en) | PKR activation via hybridization chain reaction | |
| US20190106679A1 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 | |
| JP2021503278A (ja) | ＣａｓＺ組成物及び使用方法 | |
| US20190262399A1 (en) | Compositions and methods for evaluating and modulating immune responses | |
| US6017758A (en) | DMNPE caged nucleic acid and vector | |
| WO2017075478A2 (en) | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures | |
| IL202350A (en) | Realtors of rna disorder specific to rna sequence | |
| WO2017069958A2 (en) | Modulation of novel immune checkpoint targets | |
| JP2021518160A5 (enExample) | ||
| BR112020000731A2 (pt) | métodos e sistemas para a regular condicionalmente a expressão genética | |
| JP2023547695A (ja) | 増強された免疫療法のためのシステムおよび方法 | |
| CN105396144B (zh) | 在肿瘤中差异表达的基因产物及其用途 | |
| JP2006515743A (ja) | プロテインキナーゼＡアンカー蛋白の新規なスプライシング変異体ＡＫＡＰ１８δおよびその使用 |